Jiangsu Hengrui Pharmaceuticals Co.,Ltd News

Recent Verilumia coverage about Jiangsu Hengrui Pharmaceuticals Co.,Ltd (600276.SS), including reporting-tone insights and market listing information.

• Novo licenses Hengrui obesity pill in deal worth up to $2.6B

business

Novo licenses Hengrui obesity pill in deal worth up to $2.6B

Novo Nordisk has agreed to license international development and commercialization rights to Hengrui Pharmaceuticals’ experimental obesity pill HRS1596 in a deal that could be worth up to $2.

Coverage Mix 5 source articles

Left 0% Centre 100% Right 0%

2 hours agobusiness